Jan Tužil

Mr. Jan Tužil

Value Outcomes s.r.o., Prague, Praha, Hlavní Město, Czech Republic
+1
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Value in Health
Verified
Journal Article
Closed access
TMTomas Mlcoch
Tomas Mlcoch
THTereza Hrnciarova
Tereza Hrnciarova
Jan TužilJan Tužil
Jan Tužil
JZJakub Zadak
Jakub Zadak
MMMarisca Marian
Marisca Marian
TDTomas Dolezal
Tomas Dolezal

21 November 2017 in The Patient - Patient-Centered Outcomes Research
Verified
Journal Article
Closed access
PDF file
TMTomas Mlcoch
Tomas Mlcoch
Jan TužilJan Tužil
Jan Tužil
LSLiliana Sedova
Liliana Sedova
JSJiri Stolfa
Jiri Stolfa
MUMonika Urbanova
Monika Urbanova
TDTomas Dolezal
Tomas Dolezal

21 March 2021 in Česká gynekologie
Verified
Journal Article
Closed access
Jan TužilJan Tužil
Jan Tužil
PLPrague Value Outcomes Ltd.
Prague Value Outcomes Ltd.
BFBarbora Filková
Barbora Filková
JMJiří Malina
Jiří Malina
JKJan Kerestes
Jan Kerestes
TDTomáš Doležal
Tomáš Doležal
Background: Smoking is considered a risk factor for bacterial vaginosis. It is currently unknown which parameters of the vaginal environment are affected and how smoking triggers the disease. Aim of the study: The primary objective is to estimate the effect size of smoking on vaginal pH and the Nugent score in patients with chronic vulvovaginal discomfort prior to the development of episode of vaginosis. The secondary goal is to investigate the effect of smoking on individual microscopic parameters of the vaginal environment and on subjectively reported symptoms of vaginal discomfort. Methods: Smoking reported by patients was tested as a predictor, using multivariate logistic and ordinal logistic regression analysis on a dataset from the first visit of a randomized trial NCT04171947, which enrolled patients with intermediate vaginal environment. We tested the primary hypothesis (odds ratio (OR) for vaginal pH > 4.5 and Nugent score > 3 in smokers) at the significance level alpha = 5%. For exploratory analyses of the effect of smoking on the parameters of the vaginal environment,. was corrected as per Bonferoni. Results: In a cross-sectional sample of 250 women after adjusting for other risk factors, smoking had an impact on the Nugent score (OR = 3.3 (1.3-8.5), P = 0.011), while pH was not affected (OR = 1.2 (0.5-2.8), P = 0.698). Smoking was associated with the prevalence of clue cells (P < 0.000), Gardnerella spp. (P = 0.001) and Mobiluncus spp. (P = 0.001), while the prevalence of Lactobacillus remained unchanged (P = 0.049). Conclusion: Contrarily to common assumptions, vaginal Lactobacillus is not directly affected by smoking, which rather promotes the growth of bacteria of Gardnerella and Mobiluncus spp. Given that other parameters remained unaffected, it appears that smoking leads to vaginal dysbiosis by creating specific favourable conditions for these two opportunistic pathogens.

28 October 2021 in Cerebrovascular Diseases Extra
Verified
Journal Article
Open access
PDF file
JMJan Matějka
Jan Matějka
IVIvo Varvařovský
Ivo Varvařovský
Jan TužilJan Tužil
Jan Tužil
TDTomáš Doležal
Tomáš Doležal
MBMartin Bobak
Martin Bobak
PVPetr Vojtíšek
Petr Vojtíšek
Introduction: Periprocedural stroke represents a rare but serious complication of cardiac catheterization. Pooled data from randomized trials evaluating the risk of stroke following cardiac catheterization via transradial versus transfemoral access showed no difference. On the other hand, a significant difference in stroke rates favoring transradial access was found in a recent meta-analysis of observational studies. Our aim was to determine if there is a difference in stroke risk after transradial versus transfemoral catheterization within a contemporary real-world registry. Methods: Data from 14,139 patients included in a single-center prospective registry between 2009 and 2016 were used to determine the odds of periprocedural transient ischemic attack (TIA) and stroke for radial versus femoral catheterization via multivariate logistic regression with Firth’s correction. Results: A total of 10,931 patients underwent transradial and 3,208 underwent transfemoral catheterization. Periprocedural TIA/stroke occurred in 41 (0.29%) patients. Age was the only significant predictor of TIA/stroke in multivariate analysis, with each additional year representing an odds ratio (OR) = 1.09 (CI 1.05–1.13, p < 0.000). The choice of accession site had no impact on the risk of periprocedural TIA/stroke (OR = 0.81; CI 0.38–1.72, p = 0.577). Conclusion: Observational data from a large prospective registry indicate that accession site has no influence on the risk of periprocedural TIA/stroke after cardiac catheterization.

25 November 2019 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
Jan TužilJan Tužil
Jan Tužil
TMTomáš Mlčoch
Tomáš Mlčoch
JJJitka Jirčíková
Jitka Jirčíková
JZJakub Závada
Jakub Závada
LNLucie Nekvindová
Lucie Nekvindová
TDTomáš Doležal
Tomáš Doležal
Objectives To assess the role of short-term response to first anti-TNF in long-term prediction of disability. Methods In nationwide registry ATTRA, we identified ankylosing spondylitis patients starting anti-TNF between 01/2003 and 12/2016. Full disability and work impairment (WI; WPAI questionnaire) were predicted via the Cox- and lagged-parameter mixed-effect regression. Results 2,274 biologicals-naïve patients newly indicated to anti-TNF were prospectively followed (6,333 patient-years; median follow-up 1.9 years). Reaching BASDAI < 4 (77.4%) and ASDAS-CRP < 2.1 (61.1%) after 3 months of anti-TNF both decreased the risk of future disability by ≈2.5-fold. ASDAS-CRP < 2.1 predicted non-disability better than BASDAI < 4 & CRP < 5 mg/L (p=0.032). BASDAI < 4 & CRP < 5 mg/L was comparable to BASDAI < 4 (p=0.941) and to BASDAI change by > 50% or by > 2 points (p=0.902). ASDAS-CRP change > 1.1 and > 2.0 both failed to predict non-disability. Once on anti-TNF therapy, the strongest predictor of WI was Pain (SF36). Yearly increase in indirect costs remains below €3,000 in those reaching ASDAS-CRP < 2.1. Conclusions Low disease activity measured by ASDAS-CRP ≤ 2.1 should be used to measure the outcome of new anti-TNF therapy. Continuous WI could be decreased through pain management.

20 August 2021 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Closed access
Jan TužilJan Tužil
Jan Tužil
JBJana Bartakova
Jana Bartakova
TWTorquil Watt
Torquil Watt
TDTomas Dolezal
Tomas Dolezal
Utilities of the general population or expert estimates have been used for all published cost-effectiveness analyses of screening for thyroid disorders in pregnancy.A systematic review CRD420191208...